Kastle Theraps Llc Company Profile

What is the competitive landscape for KASTLE THERAPS LLC

KASTLE THERAPS LLC has one approved drug.

There is one US patent protecting KASTLE THERAPS LLC drugs.

Summary for Kastle Theraps Llc

US Patents:	1
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Kastle Theraps Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013		DISCN	Yes	No	7,511,131			Y

Expired US Patents for Kastle Theraps Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	5,914,396
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	7,407,943
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	6,451,991
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	6,222,025
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	7,015,315
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	6,166,197

International Patents for Kastle Theraps Llc Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2336318
Spain	2417879
Australia	2003237875
Portugal	2336318
Japan	2005503142
European Patent Office	2336319

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Kastle Theraps Llc

Pharmaceutical Competitive Landscape Analysis: KASTLE THERAPS LLC – Market Position, Strengths & Strategic Insights

Last updated: July 25, 2026

Executive summary KASTLE THERAPS LLC’s competitive position is not assessable from patent, FDA product, or market-authorization records in the information provided. A defensible competitive landscape requires verifiable data inputs (drug/brand portfolio, FDA listings, Orange Book/NDA/BLA links, and patent estate or litigation records). With those inputs absent, any ranking of market position, exclusivity timelines, generic/biosimilar risk, patent strength, or litigation exposure would be non-actionable.

What pharmaceutical products does KASTLE THERAPS LLC sell and where are they approved by FDA?

Which NDA, ANDA, BLA products are tied to KASTLE THERAPS LLC

What is KASTLE THERAPS LLC’s Orange Book and FDA “active ingredient” footprint?

Which therapeutic areas does KASTLE THERAPS LLC participate in through marketed drugs

How strong is the patent estate for KASTLE THERAPS LLC’s drug portfolio?

What patents protect KASTLE THERAPS LLC marketed products (composition, method-of-use, formulation)

How many patents are listed per product in the Orange Book

Which jurisdictions likely carry the largest enforcement leverage (US only vs global filings)

When does KASTLE THERAPS LLC lose exclusivity and how many years of runway remain?

What patents expire first (drug substance vs drug product)

How does pediatric exclusivity, market exclusivity, or patent term adjustment shift launch timing

Which products face the highest early generic entry risk by paragraph IV timing

Which generic entry risks exist for KASTLE THERAPS LLC and its competitors’ ANDAs?

What paragraph IV challenges target KASTLE THERAPS LLC drugs

What is the litigation and settlement record for KASTLE THERAPS LLC portfolio

What generic launch scenarios are most likely if key patents fall

What biosimilar risk exists for KASTLE THERAPS LLC if it participates in biologics?

Which BLAs or biosimilar-relevant biologics are linked to KASTLE THERAPS LLC

What exclusivity windows apply to biologics in the portfolio

How biosimilar “switch” and interchangeability timelines could affect revenue

What formulation and delivery system patents protect KASTLE THERAPS LLC products?

What patents cover solid oral dose, controlled-release, and combination dosage forms

What manufacturing-process patents constrain alternative supply chains

Which excipients, polymorphs, and particle-size or stability claims appear in filings

How does KASTLE THERAPS LLC compare with major branded and generic competitors?

What companies compete for the same indications and market segments

Where KASTLE THERAPS LLC likely differentiates (label, device, patient support, reimbursement)

Competitive positioning vs leading generics on patent “gap” and enforcement posture

What patent litigation affects KASTLE THERAPS LLC and how does it shape licensing strategy?

Which district courts and Federal Circuit matters involve KASTLE THERAPS LLC

What settlement terms typically control entry timing and licensing economics

What licensing and consent-decree pathways are most plausible

What is the commercial exposure if major patents expire for KASTLE THERAPS LLC?

What revenue-at-risk exists by molecule, dosage form, and exclusivity expiry year

What second-generation patenting strategies reduce erosion

How channel inventory and pharmacist substitution could accelerate loss of share

Key Takeaways

No reliable competitive landscape can be produced without identifiable FDA product mappings and corresponding patent/litigation records for KASTLE THERAPS LLC. Under available information, market position, patent strength, exclusivity timing, generic/biosimilar risk, and litigation impact cannot be quantified.

FAQs

1. How can KASTLE THERAPS LLC’s Orange Book listings be used to estimate generic launch windows?
2. What indicators in patent families most strongly predict enforcement outcomes for KASTLE THERAPS LLC?
3. How do formulation patents change the risk profile for generic substitution versus label-only entry?
4. What litigation patterns typically precede Paragraph IV settlement agreements in US district courts?
5. How should biosimilar pathway selection (BLA vs 351(k)) affect competitive threat timing for KASTLE THERAPS LLC?

References

No sources were provided or identified for KASTLE THERAPS LLC FDA status, Orange Book listings, patent families, or litigation dockets.